24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publication dates

Heart Failure Industry, October 2014 Market Reports from Top Publishers

You might be interested in: medical equipment, chronic heart failure, therapeutics, more »


 
1-10 of 90 reports for Heart Failure

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • Oct 2014
  • by Firstword Pharma

... Indeed, the chronic heart failure agent is believed to represent both a significant growth driver for novartis as well as, alongside the pcsk9 class of dyslipidaemia products, among the first in a new wave of medicines ...

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... In the treatment of emphysema, chronic bronchitis, asthma with status asthmaticus, acute respiratory failure (arf), acute respiratory distress syndrome (ards), congestive heart failure with pulmonary edema ...

ARCA biopharma, Inc. (Symbol:ABIO) SWOT Analysis, Strategy, Revenues and Profits

ARCA biopharma, Inc. (Symbol:ABIO) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Tm, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure. The company offers products and services ...

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Develops medicines for the therapeutic areas, such as myocardial infarction, severe heart failure and other cardio-vascular disorders. Cardio is headquartered in kobe, hyogo, japan.This comprehensive ...

Neovasc Inc. (Symbol:NVC) SWOT Analysis, Strategy, Revenues and Profits

Neovasc Inc. (Symbol:NVC) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... And can lead to heart failure and death. Its tissue products provide treated pericardial tissue and custom development & manufacturing services to industry partners. Neovasc is headquartered in british ...

Sunshine Heart Company, Pty. Ltd. (Symbol:SHC) SWOT Analysis, Strategy, Revenues and Profits

Sunshine Heart Company, Pty. Ltd. (Symbol:SHC) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... The company designs, develops and markets medical devices for the cardiovascular market. The cardiac assist devices offered by the company are used in the treatment of severe long term heart failure and heart ...

TOA EIYO LTD. SWOT Analysis, Strategy, Revenues and Profits

TOA EIYO LTD. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... For angina pectoris, metered dose-nitroglycerin sublingual spray, nitroglycerin injection, cardiac glycosides, drugs for heart failure, anti-arrhythmic drugs and anti-arrhythmic drugs, among others ...

RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review

RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Products include rhb-101, rhb-102, rhb-103, rhb-104, rhb-105 and rhb-106. Redhill's clinical stage drug cand rhb-101 is for the treatment of congestive heart failure and high blood pressure. Rhb-102 ...

Amarantus Bioscience Holdings, Inc. (AMBS) - Financial and Strategic SWOT Analysis Review

Amarantus Bioscience Holdings, Inc. (AMBS) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Such as parkinson's disease, als and alzheimer's disease, and cardiovascular diseases including myocardial infarction, coronary artery disease and heart failure. The company holds license to eltoprazine, owns ...

Cardio3 BioSciences SA (CARD) - Financial and Strategic SWOT Analysis Review

Cardio3 BioSciences SA (CARD) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Product portfolio includes c-cure, c3bs-gqr-1, c3bs-gqr-4, c3bs-pqr-1, and c-cathez. Cardio3 biosciences products find application in the treatment of diseases such as cardiovascular diseases, heart failure ...

About 2 100 reports for Heart Failure

Download Unlimited Documents from Trusted Public Sources

Pathology Description in Norway

  • Effect of Propranolol after Acute Myocardial Infarction in Patie...
  • September 2014
    9 pages
  • Congestive Hear...  

  • Norway  

View report >

1 Companies for Heart Failure

Read our Company Profiles

Select Products Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.